Developing drugs for drug-resistant, life threatening infections.
We intend to develop and commercialize novel therapeutic agents to treat life-threatening infections, including those caused by drug-resistant pathogens. The increasing prevalence of antibiotic resistance among bacterial pathogens has been widely recognized as an urgent public health threat by the CDC, the WHO and the Infectious Disease Society of America.
Our most advanced product candidate is CF-301, a lysin for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant ("MRSA") or methicillin-susceptible Staph aureus. We also continue to explore variants of CF-301 to expand our portfolio of lysins targeting biofilm-associated Staph aureus infections. We have engineered a novel mutant variant, CF-296, which has properties we believe may make it a promising potential treatment for invasive Staph aureus infections, including prosthetic joint infections. Additionally, we are focused on researching lysin therapeutics for the treatment of infections caused by gram-negative pathogens, including multi-drug resistant strains. We also continue to progress CF-404, which is an aerosolized formulation of three human mAbs for the potential treatment of life-threatening human influenza which targets all seasonal and most pandemic strains of influenza.
*CF-301 has been granted Fast Track Designation from the FDA for the treatment of Staph aureus bacteremia.
Costs By 2050